Coronavirus antibody approval for more youthful youngsters deferred as FDA looks for additional information

Follow
Listen to Article Listen to this article read aloud

Audio uses the voice available in your browser or device.

Pfizer and BioNTech documented a solicitation with the US Food and Drug Administration in the main seven day stretch of February for a crisis use approval of their antibody in kids a half year to 5 years of age. The FDA's Vaccines and Related Biological Products Advisory Committee was planned to meet February 15 to go over information from antibody preliminaries and make a proposal on whether a two-portion immunization routine ought to be approved.

However, the FDA reported Friday that it had deferred the gathering on the grounds that "new information have as of late arisen."

The information upheld the security of the immunizations yet showed disheartening viability, the Washington Post announced Friday.

More Articles by This Writer

Support the Writer

Enjoyed this article? You can support the writer with a voluntary donation.

Your donation supports Adomba Fabreflip

Minimum donation: $2.00   •   70% of the donation is allocated to the writer after the LodPost commission.

Donate by Nigerian Bank Transfer

Send your donation in Nigerian Naira (₦). Your receipt will be reviewed by the LodPost admin before your donation is credited.

₦
Minimum donation: ₦100.00

How it works: Transfer the donation to the account above, upload your payment receipt, and our admin will verify and credit the writer.

Comments

You must be logged in to post a comment.

About Author

Member Since: Feb 08, 2022 Netherlands
0 Followers
0 Following
3 Articles
1 Likes
Related Articles